ZURICH (dpa-AFX Broker) - Swiss major bank UBS raised its price target for Fresenius to 32.50 euros from 30.50 euros and left its rating at "buy". Analyst Graham Doyle took a closer look at the company's Kabi medical subsidiary and strategic opportunities for the Fresenius Group in a report available Friday. Both are factors in his buy recommendation, but are controversial among investors. Kabi is well enough diversified to justify its annual earnings expectations through 2027, he said. Strategically, he said, only three relatively small transactions are needed to provide more time for a major transformation./tih/edh

Original study release date: 05/01/2023 / 20:36 GMT.

First disclosure of original study: 05.01.2023 / 20:36 / GMT

-----------------------

dpa-AFX Broker - Trader News from dpa-AFX

-----------------------